Ayala Pharmaceuticals (NASDAQ:ADXS) Coverage Initiated at StockNews.com

StockNews.com initiated coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a research report issued on Tuesday. The firm set a “sell” rating on the stock.

Ayala Pharmaceuticals Stock Performance

NASDAQ:ADXS opened at $0.03 on Tuesday. Ayala Pharmaceuticals has a 52 week low of $0.00 and a 52 week high of $1.49. The firm’s 50-day simple moving average is $0.03 and its 200 day simple moving average is $0.05. The firm has a market cap of $1.15 million, a price-to-earnings ratio of 0.00 and a beta of 1.62.

Ayala Pharmaceuticals Company Profile

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.